The Pfizer clot shot has received unanimous FDA approval for deployment in primary school aged children between 5 and 11 years old.
The FDA’s vaccine advisory committe voted 17-0 in favour of bringing it in, with one abstention.
The committee made it’s decision on information provided by Pfizer itself, a company with an extensive track record of fraud and corruption.
The data provided by Pfizer tracked 2,268 children in the 5-11 age group who received either the recommended regimen or a placebo. Three of the vaccinated developed symptomatic Covid-19 compared to 16 in the placebo group, according to the study conducted in August and September.
“Our comprehensive and rigorous evaluation of the data pertaining to the vaccine’s safety and effectiveness should help assure parents and guardians that this vaccine meets our high standards,” said Janet Woodcock, Acting FDA Commissioner.
Addressing concerns over myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of tissue surrounding the heart) following the Pfizer jab use in males between 12 -17 years of age, the FDA said it conducted “its own benefit-risk assessment using modelling” to see how many deaths might be caused by the vaccine versus Covid-19. Its model “predicts that overall, the benefits of the vaccine would outweigh its risks in children 5 through 11.”
The FDA’s vaccine advisory committee is currently made of up former high ranking big pharma employees, or academics with deeply rooted funding connections to big pharma.